These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6799548)

  • 1. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
    Pier GB
    J Clin Invest; 1982 Feb; 69(2):303-8. PubMed ID: 6799548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.
    Pier GB; Bennett SE
    J Clin Invest; 1986 Feb; 77(2):491-5. PubMed ID: 3080477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide.
    Pier GB; Pollack M
    Infect Immun; 1989 Feb; 57(2):426-31. PubMed ID: 2492260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysaccharide antigens of Pseudomonas aeruginosa.
    Pier GB
    Rev Infect Dis; 1988; 10 Suppl 2():S337-40. PubMed ID: 3142017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.
    Pier GB; Thomas DM
    J Infect Dis; 1983 Aug; 148(2):206-13. PubMed ID: 6411830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic basis for mouse protection provided by high-molecular-weight polysaccharide from immunotype 1 Pseudomonas aeruginosa.
    Markham RB; Pier GB
    Rev Infect Dis; 1983; 5 Suppl 5():S957-62. PubMed ID: 6419317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
    Cryz SJ; Sadoff JC; Cross AS; Fürer E
    Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.
    Hatano K; Boisot S; DesJardins D; Wright DC; Brisker J; Pier GB
    Infect Immun; 1994 Sep; 62(9):3608-16. PubMed ID: 7520416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
    Cryz SJ; Sadoff JC; Fürer E; Germanier R
    J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
    van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
    Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Sadoff JC; Ohman D; Fürer E
    J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of polysaccharides from type III, group B Streptococcus.
    Baker CJ; Edwards MS; Kasper DL
    J Clin Invest; 1978 Apr; 61(4):1107-10. PubMed ID: 96132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.
    Cryz SJ; Sadoff JC; Fürer E
    Infect Immun; 1988 Jul; 56(7):1829-30. PubMed ID: 2454893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.
    Hatano K; Pier GB
    Infect Immun; 1998 Aug; 66(8):3719-26. PubMed ID: 9673254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the antibody response in inbred mice to a high-molecular-weight polysaccharide from Pseudomonas aeruginosa immunotype 1.
    Markham RB; Pier GB
    Infect Immun; 1983 Jul; 41(1):232-6. PubMed ID: 6407998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.
    Pier GB; Pollack M; Cohen M
    Infect Immun; 1984 Aug; 45(2):309-13. PubMed ID: 6430805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.
    Pier GB; Sidberry HF; Sadoff JC
    Infect Immun; 1978 Dec; 22(3):919-25. PubMed ID: 103841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides.
    Schreiber JR; Dahlhauser P
    Infect Immun; 1994 Jan; 62(1):308-12. PubMed ID: 8262644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.
    Cripps AW; Peek K; Dunkley M; Vento K; Marjason JK; McIntyre ME; Sizer P; Croft D; Sedlak-Weinstein L
    Infect Immun; 2006 Feb; 74(2):968-74. PubMed ID: 16428742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.